Comparing benefits from sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in randomized clinical trials: a network meta-analysis-Reference-Cited by-同舟云学术

Comparing benefits from sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in randomized clinical trials: a network meta-analysis

Published:2023-03 Issue:2 Volume:71 Page:
ISSN:2724-5683
Container-title:Minerva Cardiology and Angiology
language:
Short-container-title:Minerva Cardiol Angiol

Author:

SABOURET Pierre,BOCCHINO Pier P.,ANGELINI Filippo,D’ASCENZO Fabrizio,GALATI Giuseppe,FYSEKIDIS Marinos,DE FERRARI Gaetano M.,FISCHMAN David L.,BHATT Deepak L.,BIONDI-ZOCCAI Giuseppe

Publisher

Edizioni Minerva Medica

Subject

Cardiology and Cardiovascular Medicine

Link

https://www.minervamedica.it/pdf.php?cod=R05Y2023N02A0199

Reference42 articles.

1. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD

2. Excess Mortality among Persons with Type 2 Diabetes

3. Age at Diagnosis of Type 2 Diabetes Mellitus and Associations With Cardiovascular and Mortality Risks

4. DECLARE‐TIMI 58: Participants’ baseline characteristics

5. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Empagliflozin: Primus Inter Pares Among Sodium–Glucose Cotransporter-2 Inhibitors?;Journal of Cardiovascular Pharmacology;2024-09

2. New Developments in Pharmacological Treatment of Obesity and Type 2 Diabetes—Beyond and within GLP-1 Receptor Agonists;Biomedicines;2024-06-13

3. A New Hope on the Horizon for Kidney and Cardiovascular Protection with SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Mineralocorticoid Receptor Antagonists in Type 2 Diabetic and Chronic Kidney Disease Patients;Metabolic Syndrome and Related Disorders;2024-04-01

4. Cardiovascular protection significantly depends on HbA1c improvement with GLP-1RAs but not with SGLT2 is in type 2 diabetes: a narrative review;Diabetes & Metabolism;2023-12

5. What about glucagon-like peptide-1 receptor agonist for all? Recent data and perspectives;European Heart Journal;2023-10-04